Macquarie Group Ltd. Boosts Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Macquarie Group Ltd. boosted its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 655,940 shares of the biopharmaceutical company’s stock after purchasing an additional 10,871 shares during the period. Macquarie Group Ltd. owned approximately 1.58% of Intercept Pharmaceuticals worth $9,159,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Delphia USA Inc. raised its stake in Intercept Pharmaceuticals by 4.6% during the second quarter. Delphia USA Inc. now owns 17,109 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 756 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Intercept Pharmaceuticals by 0.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 157,510 shares of the biopharmaceutical company’s stock worth $2,175,000 after acquiring an additional 795 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in shares of Intercept Pharmaceuticals by 0.5% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 164,210 shares of the biopharmaceutical company’s stock worth $2,672,000 after acquiring an additional 825 shares in the last quarter. Rhumbline Advisers increased its position in shares of Intercept Pharmaceuticals by 4.3% in the second quarter. Rhumbline Advisers now owns 29,409 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 1,210 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Intercept Pharmaceuticals by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 105,729 shares of the biopharmaceutical company’s stock worth $1,720,000 after acquiring an additional 2,644 shares in the last quarter. Hedge funds and other institutional investors own 81.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ICPT shares. SVB Securities increased their price objective on shares of Intercept Pharmaceuticals from $17.00 to $18.00 in a research report on Friday. Royal Bank of Canada increased their price objective on shares of Intercept Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Friday. HC Wainwright lowered their price target on shares of Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, November 16th. Needham & Company LLC raised their price target on shares of Intercept Pharmaceuticals from $22.00 to $26.00 and gave the company a “buy” rating in a report on Friday. Finally, Raymond James raised their price target on shares of Intercept Pharmaceuticals from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Sunday. Four analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Intercept Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.00.

Intercept Pharmaceuticals Stock Down 1.0 %

Intercept Pharmaceuticals stock opened at $20.48 on Tuesday. The stock has a market cap of $848.22 million, a price-to-earnings ratio of 3.17 and a beta of 1.29. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 2.40. The company’s 50-day moving average price is $17.57 and its two-hundred day moving average price is $16.05. Intercept Pharmaceuticals, Inc. has a 52 week low of $10.81 and a 52 week high of $21.86.

Intercept Pharmaceuticals Profile

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.